Back to Browse Journals » Clinical Epidemiology » Volume 5 » Issue 1

The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)

Authors Höybye C, Sävendahl L, Christesen HT, Lee P, Pedersen BT, Schlumpf M, Germak J, Ross J

Published Date April 2013 Volume 2013:5(1) Pages 119—127

DOI http://dx.doi.org/10.2147/CLEP.S42602

Received 10 January 2013, Accepted 13 February 2013, Published 26 April 2013

Charlotte Höybye,1 Lars Sävendahl,2 Henrik Thybo Christesen,3 Peter Lee,4 Birgitte Tønnes Pedersen,5 Michael Schlumpf,6 John Germak,7 Judith Ross8

1Department of Molecular Medicine and Surgery, Karolinska Institute and Department of Endocrinology, Metabolism and Diabetes, 2Department of Women’s and Children’s Health, Karolinska Institute and Division of Pediatrics, Karolinska University Hospital, Stockholm, Sweden; 3Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark; 4Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA; 5Global Development, Novo Nordisk A/S, Søborg, Denmark; 6Global Medical Affairs Biopharm, Novo Nordisk Health Care AG, Zurich, Switzerland; 7Clinical Development and Medical Affairs, Novo Nordisk Inc, Princeton, NJ, USA; 8Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA, USA

Objective: Randomized controlled trials have shown that growth hormone (GH) therapy has effects on growth, metabolism, and body composition. GH therapy is prescribed for children with growth failure and adults with GH deficiency. Carefully conducted observational study of GH treatment affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables affecting those outcomes, in patients receiving GH therapy in routine clinical practice.
Design: The NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web Enabled Research (ANSWER Program®) are two complementary, non-interventional, observational studies that adhere to current guidelines for pharmacoepidemiological data.
Patients: The studies include pediatric and adult patients receiving Norditropin®, as prescribed by their physicians.
Measurements: The studies gather long-term data on the safety and effectiveness of real-life treatment with the recombinant human GH, Norditropin®. We describe the origins, aims, objectives, and design methodology of the studies, as well as their governance and validity, strengths, and limitations.
Conclusion: The NordiNet® IOS and ANSWER Program® studies will provide valid insights into the effectiveness and safety of GH treatment across a diverse and large patient population treated in accordance with real-world clinical practice and following the Good Pharmacoepidemiological Practice and STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines.

Keywords: growth hormone replacement therapy, treatment outcome, pharmacoepidemiology, survey

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Noninvasive detection of macrophages in atherosclerotic lesions by computed tomography enhanced with PEGylated gold nanoparticles

Qin J, Peng C, Zhao B, Ye K, Yuan F, Peng Z, Yang X, Huang L, Jiang M, Zhao Q, Tang G, Lu X

International Journal of Nanomedicine 2014, 9:5575-5590

Published Date: 2 December 2014

Mesenchymal stromal cell labeling by new uncoated superparamagnetic maghemite nanoparticles in comparison with commercial Resovist – an initial in vitro study

Skopalik J, Polakova K, Havrdova M, Justan I, Magro M, Milde D, Knopfova L, Smarda J, Polakova H, Gabrielova E, Vianello F, Michalek J, Zboril R

International Journal of Nanomedicine 2014, 9:5355-5372

Published Date: 20 November 2014

Self-assembled nanoparticles based on the c(RGDfk) peptide for the delivery of siRNA targeting the VEGFR2 gene for tumor therapy

Liu L, Liu X, Xu Q, Wu P, Zuo X, Zhang J, Deng H, Wu Z, Ji A

International Journal of Nanomedicine 2014, 9:3509-3526

Published Date: 29 July 2014

In situ precipitation: a novel approach for preparation of iron-oxide magnetoliposomes

Xia S, Li P, Chen Q, Armah M, Ying X, Wu J, Lai J

International Journal of Nanomedicine 2014, 9:2607-2617

Published Date: 23 May 2014

Efficiently engineered cell sheet using a complex of polyethylenimine–alginate nanocomposites plus bone morphogenetic protein 2 gene to promote new bone formation

Jin H, Zhang K, Qiao C, Yuan A, Li D, Zhao L, Shi C, Xu X, Ni S, Zheng C, Liu X, Yang B, Sun H

International Journal of Nanomedicine 2014, 9:2179-2190

Published Date: 7 May 2014

Astigmatism induced by conventional spherical ablation after PRK and LASIK in myopia with astigmatism < 1.00 D

Christiansen SM, Mifflin MD, Edmonds JN, Simpson RG, Moshirfar M

Clinical Ophthalmology 2012, 6:2109-2117

Published Date: 20 December 2012

Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice

Liu Z, Li J, Li J, Huang J, Ke F, Qi Q, Jiang X, Zhong Z

International Journal of Nanomedicine 2012, 7:5039-5049

Published Date: 17 September 2012

Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells

Kumar M, Singh G, Arora V, Mewar S, Sharma U, Jagannathan NR, Sapra S, Dinda AK, Kharbanda S, Singh H

International Journal of Nanomedicine 2012, 7:3503-3516

Published Date: 6 July 2012

Hydrophobic ion pairing of an insulin-sodium deoxycholate complex for oral delivery of insulin

Sun S, Liang N, Kawashima Y, Xia D, Cui F

International Journal of Nanomedicine 2011, 6:3049-3056

Published Date: 28 November 2011